- Home
- PUBM vs CRVS Comparison
PUBM vs CRVS Comparison
Compare PUBM & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PUBM
- CRVS
- Stock Information
- Founded
- PUBM 2006
- CRVS 2014
- Country
- PUBM United States
- CRVS United States
- Employees
- PUBM N/A
- CRVS N/A
- Industry
- PUBM Computer Software: Prepackaged Software
- CRVS Biotechnology: Pharmaceutical Preparations
- Sector
- PUBM Technology
- CRVS Health Care
- Exchange
- PUBM Nasdaq
- CRVS Nasdaq
- Market Cap
- PUBM 382.7M
- CRVS 459.0M
- IPO Year
- PUBM 2020
- CRVS 2016
- Fundamental
- Price
- PUBM $8.22
- CRVS $5.83
- Analyst Decision
- PUBM Buy
- CRVS Strong Buy
- Analyst Count
- PUBM 11
- CRVS 4
- Target Price
- PUBM $18.05
- CRVS $15.00
- AVG Volume (30 Days)
- PUBM 626.1K
- CRVS 596.5K
- Earning Date
- PUBM 11-11-2025
- CRVS 11-11-2025
- Dividend Yield
- PUBM N/A
- CRVS N/A
- EPS Growth
- PUBM N/A
- CRVS N/A
- EPS
- PUBM N/A
- CRVS N/A
- Revenue
- PUBM $292,208,000.00
- CRVS N/A
- Revenue This Year
- PUBM N/A
- CRVS N/A
- Revenue Next Year
- PUBM $1.70
- CRVS N/A
- P/E Ratio
- PUBM N/A
- CRVS N/A
- Revenue Growth
- PUBM 3.53
- CRVS N/A
- 52 Week Low
- PUBM $7.01
- CRVS $2.54
- 52 Week High
- PUBM $17.74
- CRVS $10.00
- Technical
- Relative Strength Index (RSI)
- PUBM 38.83
- CRVS 58.56
- Support Level
- PUBM $8.04
- CRVS $5.90
- Resistance Level
- PUBM $8.54
- CRVS $6.30
- Average True Range (ATR)
- PUBM 0.31
- CRVS 0.32
- MACD
- PUBM 0.11
- CRVS -0.00
- Stochastic Oscillator
- PUBM 18.97
- CRVS 53.92
About PUBM PubMatic Inc.
PubMatic Inc is a supply-side platform provider in the digital advertising technology market. These platforms help publishers, which supply digital ad inventory, manage their inventory, selling a high percentage of their inventory (increase the ad fill rate) and maximizing revenue per ad sold (optimize yield). The company generates revenue mainly by taking a piece of the ad sales that it enables. Buyers on the platform include intermediary buyers, such as demand-side platforms, or advertisers and ad agencies directly. Geographically, the company generates the majority of its revenue from the United States, followed by EMEA and APAC.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).